HR Execs on the Move

Aegerion

www.aegerion.com

 
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.aegerion.com
  • One Main Street Suite 800
    Cambridge, MA USA 02142
  • Phone: 855.305.2347

Executives

Name Title Contact Details
Kelley Morse
Associate Director of Human Resources Profile

Similar Companies

Aviva Labs Inc

Aviva Labs Inc is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tetracore

At Tetracore, we focus on animal health, domestic preparedness, antibody, clinical, and immunology products. View our products online.

aTyr Pharma

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

Carmell Therapeutics

Our groundbreaking plasma-based materials are designed to improve patient outcomes and reduce healthcare costs across a variety of surgical procedures.

Invivyd

Invivyd is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd`s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications.